Skip to Content

Meta Analysis of Three Trials: FAST, SPOTLIGHT & GLOW Exploring the New Target Claudin 18.2 in Gastric Cancer

Presented at ASCO GI, Davi Said Gonçalves Celso, critically evaluates zolbetuximab’s efficacy through a meta-analysis of three key trials: FAST, SPOTLIGHT, and GLOW. This analysis, involving 1,349 patients, demonstrates zolbetuximab’s significant potential in reducing disease progression and mortality, particularly in patients lacking HER2 and PD-L1 CPS markers.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top